-
Deutsche Bank Raises Achillion Price Target 183%
Monday, August 18, 2014 - 8:28am | 242Read More...Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and raised the price target from $6 to $17. In the past, key concerns surrounded clinical and management execution. However, analyst Alethia Young writes that execution...
-
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly
Friday, June 27, 2014 - 3:49pm | 468Read More...Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive acquisition, earlier this month, sent shares of other Hep C companies, Enanta (NASDAQ: ENTA) and Achillion (NASDAQ: ACHN) higher. In an exclusive interview with...
